X0508 4 2023-09-19 true 0001825367 RayzeBio, Inc. RYZB 0001739920 venBio Global Strategic Fund III, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001869303 VENBIO GLOBAL STRATEGIC GP III, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001869300 VENBIO GLOBAL STRATEGIC GP III, LTD 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001329161 Adelman Robert J 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001278411 GOODMAN COREY S 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true false Common Stock 2023-09-19 4 C 0 3786957 A 3786957 D Common Stock 2023-09-19 4 C 0 1123862 A 4910819 D Common Stock 2023-09-19 4 C 0 247343 A 5158162 D Series A Convertible Preferred Stock 2023-09-19 4 C 0 3786957 D Common Stock 3786957 0 D Series B Convertible Preferred Stock 2023-09-19 4 C 0 1123862 D Common Stock 1123862 0 D Series C Convertible Preferred Stock 2023-09-19 4 C 0 216127 D Common Stock 247343 0 D Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date. Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. Each share of Series C Convertible Preferred Stock (the "Series C Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date. These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein. Dr. Aaron Royston serves as a member of the Issuer's board of directors and is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III. venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21 venBio Global Strategic GP III, L.P., by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 2023-09-21 venBio Global Strategic GP III, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21 Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21 Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21